Futibatinib
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) [1][2][3].
Product Specifications
CAS Number
1448169-71-8
Product Name Alternative
TAS-120
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/FGFR-IN-1.html
Purity
99.90
Solubility
DMSO : ≥ 29 mg/mL
Smiles
O=C(C=C)N(C1)CC[C@@H]1N(N=C2C#CC3=CC(OC)=CC(OC)=C3)C4=C2C(N)=NC=N4
Molecular Formula
C22H22N6O3
Molecular Weight
418.45
Precautions
H302, H315, H319, H335
References & Citations
[1]Goyal L, et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 Aug;9 (8) :1064-1079.|[2]Kalyukina M, et al. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem. 2019 Feb 19;14 (4) :494-500.|[3]Lamarca A, et al. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer [published online ahead of print, 2020 Mar 12]. J Hepatol. 2020; S0168-8278 (20) 30165-3.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC550393-500 1x 500 µL
Cytokeratin, multi (C11), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-D434977-50MG 50 mg
1-(2,3-Dichloro-4-hydroxyphenyl)butan-1-one-d7
Sign In for Pricing
View Details 